Tag: Immune checkpoint inhibition
Limited Benefit of Nivolumab/Tivozanib in Advanced RCC Post-Immunotherapy
The combination of nivolumab and tivozanib did not show an improvement in progression-free survival (PFS) for patients with advanced metastatic renal cell carcinoma (RCC)...